PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420357
PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1420357
The global mycobacterium tuberculosis treatment market, valued at US$ 2.15 billion in 2024, is poised for steady growth, according to a comprehensive study by Fairfield Market Research. The market is expected to approximately US$ 2.4 billion by the end of 2031.
Tuberculosis remains a pressing global health issue, with 1.6 million deaths reported worldwide in 2021, making it the second leading infectious killer globally, following COVID-19 and HIV/AIDS. There were approximately 10.6 million reported cases of tuberculosis in 2021, affecting people of all ages.
The COVID-19 pandemic had a significant impact on tuberculosis diagnosis and treatment in 2020, leading to a 21% decline in TB treatment compared to 2019. Restrictions on movement, resource reallocation, and insufficient equipment and capacity hampered the provision of tuberculosis services.
Despite these challenges, the market for mycobacterium tuberculosis treatment is set to exhibit growth over the coming years. Government initiatives and National Strategic Plans aimed at eradicating tuberculosis by 2025 are expected to fuel steady growth in the market.
The availability of generic alternatives to tuberculosis medications has led to a wide range of low-cost prescription options. As branded pharmaceuticals lose patent protection, pharmaceutical companies face competition from generic drugs. This competition is expected to increase as more drugs enter the market, impacting manufacturers of original products.
United States: The U.S. is a significant player in the global Mycobacterium Tuberculosis Treatment Market. The incidence of tuberculosis has been on the rise among both U.S.-born and non-U.S.-born individuals, contributing to market growth. The U.S. government is a major contributor to international funding for TB programs, which further supports market development.
China: China is emerging as a prominent market for Mycobacterium Tuberculosis drug suppliers in East Asia. The country has a high burden of latent tuberculosis infection (LTBI), with millions of people at risk for active TB illness. The Chinese government has initiated programs like the Healthy China Initiative 2024-2031, including Tuberculosis Control Action, which is expected to drive market growth.
India: India has a significant share of the South Asian market for Mycobacterium Tuberculosis treatment. The country has a high prevalence of tuberculosis and drug-resistant tuberculosis (MDR-TB). The incidence of tuberculosis has been increasing, and there are ongoing digital initiatives, such as #BeTheChangeForTB, supported by government and international agencies, to combat the disease.
Key players in the mycobacterium tuberculosis treatment industry are actively engaged in activities such as new product launches, acquisitions, collaborations, and expansion to advance and develop new products and therapies.